Bruker (NASDAQ:BRKR) Releases FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.100-2.150 for the period, compared to the consensus EPS estimate of 2.120. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Upgrades and Downgrades

BRKR has been the topic of a number of research reports. Leerink Partners boosted their price objective on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. JPMorgan Chase & Co. upped their target price on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Stifel Nicolaus set a $45.00 price target on Bruker in a report on Friday, May 8th. Finally, Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $56.79.

Bruker Price Performance

Shares of BRKR stock opened at $52.52 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The company has a market cap of $8.00 billion, a P/E ratio of -219.52, a PEG ratio of 2.01 and a beta of 1.28. The stock’s 50-day moving average is $58.52 and its 200 day moving average is $46.70. Bruker has a 1-year low of $28.53 and a 1-year high of $65.30.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. Bruker’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts predict that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio is presently -83.33%.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC acquired a new position in Bruker during the fourth quarter worth $26,000. Allworth Financial LP raised its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares in the last quarter. Summit Securities Group LLC acquired a new stake in shares of Bruker during the fourth quarter worth about $50,000. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Bruker by 144.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 876 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.